Cargando…

A novel strategy to avoid sensitivity loss in pooled testing for SARS-CoV-2 surveillance: validation using nasopharyngeal swab and saliva samples

At the peak of the COVID-19 pandemic, pooled surveillance strategies were employed to alleviate the overwhelming demand for clinical testing facilities. A major drawback of most pooled-testing methods is the dilution of positive samples, which leads to a loss of detection sensitivity and the potenti...

Descripción completa

Detalles Bibliográficos
Autores principales: Millward, Georgia G., Popelka, Shane M., Gutierrez, Anthony G., Kowallis, William J., von Tersch, Robert L., Yerramilli, Subrahmanyam V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10450028/
https://www.ncbi.nlm.nih.gov/pubmed/37637813
http://dx.doi.org/10.3389/fpubh.2023.1190308
_version_ 1785095101342547968
author Millward, Georgia G.
Popelka, Shane M.
Gutierrez, Anthony G.
Kowallis, William J.
von Tersch, Robert L.
Yerramilli, Subrahmanyam V.
author_facet Millward, Georgia G.
Popelka, Shane M.
Gutierrez, Anthony G.
Kowallis, William J.
von Tersch, Robert L.
Yerramilli, Subrahmanyam V.
author_sort Millward, Georgia G.
collection PubMed
description At the peak of the COVID-19 pandemic, pooled surveillance strategies were employed to alleviate the overwhelming demand for clinical testing facilities. A major drawback of most pooled-testing methods is the dilution of positive samples, which leads to a loss of detection sensitivity and the potential for false negatives. We developed a novel pooling strategy that compensates for the initial dilution with an appropriate concentration during nucleic acid extraction and real-time PCR. We demonstrated the proof of principle using laboratory-created 10-sample pools with one positive and corresponding individual positive samples by spiking a known amount of heat-inactivated SARS-CoV-2 into viral transport medium (VTM) or pooled negative saliva. No Ct difference was observed between a 10-sample pool with one positive vs. the corresponding individually analyzed positive sample by this method, suggesting that there is no detectable loss of sensitivity. We further validated this approach by using nasopharyngeal swab (NPS) specimens and showed that there is no loss of sensitivity. Serial dilutions of the virus were spiked into VTM and pooled with negative saliva in simulated 10-sample pools containing one positive to determine the LOD and process efficiency of this pooling methodology. The LOD of this approach was 10 copies/PCR, and the process efficiencies are ~95%−103% for N1 and ~87%−98% for N2 with samples in different matrices and with two different master mixes tested. Relative to TaqPath 1-step master mix, the TaqMan Fast Virus 1-Step master mix showed better sensitivity for the N2 assay, while the N1 assay showed no Ct difference. Our pooled testing strategy can facilitate large-scale, cost-effective SARS-CoV-2 surveillance screening and maintain the same level of sensitivity when analyzed individually or in a pool. This approach is highly relevant for public health surveillance efforts aimed at mitigating SARS-CoV-2 spread.
format Online
Article
Text
id pubmed-10450028
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-104500282023-08-26 A novel strategy to avoid sensitivity loss in pooled testing for SARS-CoV-2 surveillance: validation using nasopharyngeal swab and saliva samples Millward, Georgia G. Popelka, Shane M. Gutierrez, Anthony G. Kowallis, William J. von Tersch, Robert L. Yerramilli, Subrahmanyam V. Front Public Health Public Health At the peak of the COVID-19 pandemic, pooled surveillance strategies were employed to alleviate the overwhelming demand for clinical testing facilities. A major drawback of most pooled-testing methods is the dilution of positive samples, which leads to a loss of detection sensitivity and the potential for false negatives. We developed a novel pooling strategy that compensates for the initial dilution with an appropriate concentration during nucleic acid extraction and real-time PCR. We demonstrated the proof of principle using laboratory-created 10-sample pools with one positive and corresponding individual positive samples by spiking a known amount of heat-inactivated SARS-CoV-2 into viral transport medium (VTM) or pooled negative saliva. No Ct difference was observed between a 10-sample pool with one positive vs. the corresponding individually analyzed positive sample by this method, suggesting that there is no detectable loss of sensitivity. We further validated this approach by using nasopharyngeal swab (NPS) specimens and showed that there is no loss of sensitivity. Serial dilutions of the virus were spiked into VTM and pooled with negative saliva in simulated 10-sample pools containing one positive to determine the LOD and process efficiency of this pooling methodology. The LOD of this approach was 10 copies/PCR, and the process efficiencies are ~95%−103% for N1 and ~87%−98% for N2 with samples in different matrices and with two different master mixes tested. Relative to TaqPath 1-step master mix, the TaqMan Fast Virus 1-Step master mix showed better sensitivity for the N2 assay, while the N1 assay showed no Ct difference. Our pooled testing strategy can facilitate large-scale, cost-effective SARS-CoV-2 surveillance screening and maintain the same level of sensitivity when analyzed individually or in a pool. This approach is highly relevant for public health surveillance efforts aimed at mitigating SARS-CoV-2 spread. Frontiers Media S.A. 2023-08-10 /pmc/articles/PMC10450028/ /pubmed/37637813 http://dx.doi.org/10.3389/fpubh.2023.1190308 Text en Copyright © 2023 Millward, Popelka, Gutierrez, Kowallis, von Tersch and Yerramilli. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Public Health
Millward, Georgia G.
Popelka, Shane M.
Gutierrez, Anthony G.
Kowallis, William J.
von Tersch, Robert L.
Yerramilli, Subrahmanyam V.
A novel strategy to avoid sensitivity loss in pooled testing for SARS-CoV-2 surveillance: validation using nasopharyngeal swab and saliva samples
title A novel strategy to avoid sensitivity loss in pooled testing for SARS-CoV-2 surveillance: validation using nasopharyngeal swab and saliva samples
title_full A novel strategy to avoid sensitivity loss in pooled testing for SARS-CoV-2 surveillance: validation using nasopharyngeal swab and saliva samples
title_fullStr A novel strategy to avoid sensitivity loss in pooled testing for SARS-CoV-2 surveillance: validation using nasopharyngeal swab and saliva samples
title_full_unstemmed A novel strategy to avoid sensitivity loss in pooled testing for SARS-CoV-2 surveillance: validation using nasopharyngeal swab and saliva samples
title_short A novel strategy to avoid sensitivity loss in pooled testing for SARS-CoV-2 surveillance: validation using nasopharyngeal swab and saliva samples
title_sort novel strategy to avoid sensitivity loss in pooled testing for sars-cov-2 surveillance: validation using nasopharyngeal swab and saliva samples
topic Public Health
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10450028/
https://www.ncbi.nlm.nih.gov/pubmed/37637813
http://dx.doi.org/10.3389/fpubh.2023.1190308
work_keys_str_mv AT millwardgeorgiag anovelstrategytoavoidsensitivitylossinpooledtestingforsarscov2surveillancevalidationusingnasopharyngealswabandsalivasamples
AT popelkashanem anovelstrategytoavoidsensitivitylossinpooledtestingforsarscov2surveillancevalidationusingnasopharyngealswabandsalivasamples
AT gutierrezanthonyg anovelstrategytoavoidsensitivitylossinpooledtestingforsarscov2surveillancevalidationusingnasopharyngealswabandsalivasamples
AT kowalliswilliamj anovelstrategytoavoidsensitivitylossinpooledtestingforsarscov2surveillancevalidationusingnasopharyngealswabandsalivasamples
AT vonterschrobertl anovelstrategytoavoidsensitivitylossinpooledtestingforsarscov2surveillancevalidationusingnasopharyngealswabandsalivasamples
AT yerramillisubrahmanyamv anovelstrategytoavoidsensitivitylossinpooledtestingforsarscov2surveillancevalidationusingnasopharyngealswabandsalivasamples
AT millwardgeorgiag novelstrategytoavoidsensitivitylossinpooledtestingforsarscov2surveillancevalidationusingnasopharyngealswabandsalivasamples
AT popelkashanem novelstrategytoavoidsensitivitylossinpooledtestingforsarscov2surveillancevalidationusingnasopharyngealswabandsalivasamples
AT gutierrezanthonyg novelstrategytoavoidsensitivitylossinpooledtestingforsarscov2surveillancevalidationusingnasopharyngealswabandsalivasamples
AT kowalliswilliamj novelstrategytoavoidsensitivitylossinpooledtestingforsarscov2surveillancevalidationusingnasopharyngealswabandsalivasamples
AT vonterschrobertl novelstrategytoavoidsensitivitylossinpooledtestingforsarscov2surveillancevalidationusingnasopharyngealswabandsalivasamples
AT yerramillisubrahmanyamv novelstrategytoavoidsensitivitylossinpooledtestingforsarscov2surveillancevalidationusingnasopharyngealswabandsalivasamples